Background:
According to the World Health Organization, osteoarthritis (OA) is one of
the 10 most disabling diseases in developed countries, with worldwide estimates of 9.6% prevalence
in men and 18.0% in women over 60 years old. Its management is not well established and involves
the use of high doses of painkillers coupled with anti-inflammatory agents.
background:
According to the World Health Organization, osteoarthritis (OA) is one of the 10 most disabling diseases in developed countries, with worldwide estimates of 9.6% prevalence in men and 18.0% in women over 60 years old. Its management is not well established and involves the use of high doses of painkillers coupled with anti-inflammatory agents.
Objective:
In the search for alternatives to manage the disease, previous studies have shown superior properties of Q-ActinTM in managing OA-related pain compared with standard treatments. Qactin is a cucumber extract with the anti-inflammatory iminosugar idoBR1 standardised to over 1%.
This study investigated the effects of different doses (20 mg, 100 mg) of Q-Actin in a longitudinal
placebo-controlled experiment.
objective:
In the search for alternatives to manage the disease, previous studies have shown superior properties of Q-ActinTM in managing OA-related pain compared with standard treatments. Q-actin is a cucumber extract with the anti-inflammatory iminosugar idoBR1 standardised to over 1%. This study investigated the effects of different doses (20 mg, 100 mg) of Q-Actin in a longitudinal placebo-controlled experiment.
Methods:
There were 101 patients with knee OA enrolled for the 180-day study, with 91 patients
completing it. Patients were grouped into a placebo group (PLBO), as well as a 20-mg dose (QActin 1) and 100-mg dose (Q-Actin 2) groups. The PLBO group received cellulose in capsules
identical to the Q-Actin capsules.
method:
There were 101 patients with knee OA enrolled for the 180-day study, with 91 patients completing. Patients were grouped into a placebo group (PLBO), as well as a 20-mg dose (Q-Actin 1) and 100-mg dose (Q-Actin 2) groups. The PLBO group received cellulose in capsules identical to the Q-Actin capsules.
Results:
There was a significant improvement in the pain-related parameters over time that was
dose-depende
result:
There was a significant improvement on the pain-related parameters over time that was dose-dependent.
Conclusion:
This study clearly demonstrated the effectiveness of Q-Actin compared to placebo in
the management of pain related to moderate osteoarthritis.
other:
NA